All-Cause and Pneumococcal Community-Acquired Pneumonia Hospitalizations Among Adults in Tennessee and Georgia

What is the incidence of hospitalizations for community-acquired pneumonia (CAP), pneumococcal CAP, and pneumococcal CAP that can be potentially prevented with the recently approved adult-specific 21-valent pneumococcal conjugate vaccine (V116)?In this cross-sectional study including adults residing in defined catchment areas in Tennessee and Georgia, the overall annual incidence of hospitalizations for all-cause CAP was 340 per 100 000 adults. The incidence of hospitalizations for pneumococcal CAP was 43 per 100 000 adults, and for pneumococcal CAP due to serotypes included in V116 was 30 per 100 000 adults.There is a large burden of hospitalizations for CAP among US adults; these results suggest a sizable fraction of CAP was caused by , especially by serotypes covered by V116.

Corresponding Author: Carlos G. Grijalva, MD, MPH, (carlos.grijalva@vumc.org), and Wesley H. Self, MD, MPH (Wesley.self@vumc.org), Vanderbilt University Medical Center, 2525 West End Ave, Ste 714, Nashville, TN 37203.

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.